The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Helen F. Graham Cancer Center receives $1M gift to advance cancer care and reduce disparities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ChristianaCare received a $1 million gift from the Bacchieri Family to support the purchase of a state-of-the-art radiography system to analyze breast cancer specimens at the Helen F. Graham Cancer Center & Research Institute and expand a fellowship program to reduce disparities in breast and lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

ChristianaCare study identifies potential drug combination for making CRC more responsive to retinoids

A study from researchers at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute identifies a potential way to make colorectal cancer more responsive to retinoids, compounds related to vitamin A that can help regulate how cells grow and mature. The article “Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: Basis for new drug combinations in oncology,” 
Clinical Roundup

Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account